EWEloise Watson

Eloise Watson

*This is an algorithmically generated author record based on publicly available information.

Eloise Watson has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mitochondrial Disease variation in healthy older adults: a genotype-phenotype assessment linking pathogenic variants and mitochondrial constraint

    by Eloise Watson, Gordon Qian, Shyamsundar Ravishankar, Matthew Hobbs, Joseph Copty, Chenglong Yu, Sarah Kummerfeld, Christina Liang, Paul Lacaze, Ryan L. Davis, et al.

    Mitochondrial diseases (MDs) are caused by variants in the mitochondrial (mtDNA) or nuclear (nDNA) genome and encompass a diverse disease spectrum, whilst mitochondrial dysfunction more broadly is implicated in aging and neurodegeneration, with distinct and overlapping phenotypic features. Recent population genomic studies reveal pathogenic MD variation to be common in the population and somatic mtDNA variants accumulate from the seventh decade. Cumulative burden of mtDNA variation, quantified using mitochondrial genome constraint measures, may mediate mitochondrial dysfunction generally. However, the clinical relevance of incidentally identified variation for MDs, and of mitochondrial constraint measures for aging and neurodegeneration, is unclear. We have quantified pathogenic mtDNA and nDNA variation, as well as measures of mitochondrial genome constraint in the Medical Genome Reference Bank (MGRB), a cohort of healthy older individuals. We evaluated association of identified pathogenic MD variants with clinical features relevant to MD across four domains including physical function, cognitive function, endocrine-metabolic function and mood. Associations of mitochondrial genome constraint with clinical measures of aging and neurodegeneration were also explored. No significant associations between MD variants and phenotypes were identified, although surprisingly, mood measures appeared healthier for variant carriers compared to non-carriers. Summed mtDNA constraint showed significant inverse association with blood pressure and a trend toward inverse association with physical function. Measures of cognitive function did not demonstrate association with summed or mean mitochondrial genome constraint. Pathogenic MD variants are relatively common in the population and may be carried through to old age in good health, emphasising the importance of clinical context for counselling. Mitochondrial genome constraint measures warrant further evaluation as a surrogate biomarker for mitochondrial genome quality and mitochondrial dysfunction.

  • Open Access

    Pathogenic mitochondrial genome variation, heteroplasmy thresholding and mitochondrial constraint measures in a healthy older cohort

    by Eloise Watson, Gordon Qian, Shyamsundar Ravishankar, Matthew Hobbs, Joseph Copty, Chenglong Yu, Sarah Kummerfeld, Christina Liang, Paul Lacaze, Ryan L. Davis, et al.

    Mitochondrial diseases (MDs) are clinically heterogeneous rendering ascertainment challenging. Estimates of pathogenic mitochondrial DNA (mtDNA) variants in the population range from 1 in 200 to 1 in 4,000 individuals. Inclusion of mtDNA sequencing in genomic databases facilitates comprehensive estimation of mtDNA variation. However, interpretation of low heteroplasmy variation is complex, due in part to misalignment of nuclear mitochondrial DNA transcripts (NUMTs), whilst conservative heteroplasmy thresholds likely omit relevant variation. Cumulative burden of mtDNA variation contributes to aging and neurodegeneration, and recent characterisation of mitochondrial genome constraint allows quantitation of this burden. We analysed whole genome sequencing of blood DNA from 3,500 healthy older individuals in the Medical Genome Reference Bank using mity , considering pathogenic mtDNA variants ≥1% heteroplasmy. We identified 34 distinct pathogenic mtDNA variants in 62 individuals, giving a combined population allele frequency of 1.77% (95% CI 1.36-2.27) or 1 in 56 individuals. We evaluated inclusion of false positive (FP) calls due to two common NUMTs, which accounted for up to 16% of variants. Increasing heteroplasmy thresholding to eliminate all NUMT-FPs also eliminated much of the total variation, including pathogenic variants. We propose a sample-specific, scaled heteroplasmy threshold to maximise variant retention and mitigate NUMT-FPs. Finally, we characterised measures of mitochondrial constraint in this healthy older cohort, observing an association between variant burden and summed constraint, whilst mean constraint was higher in pathogenic variant carriers. These findings suggest pathogenic mtDNA variation is more common in the population than is currently appreciated. Findings are comparable to larger genomic databases when heteroplasmy thresholding is adjusted, and support earlier population-based estimates. Incorporation of low heteroplasmy variation is relevant, but interpretation is nuanced, and optimising variant retention requires consideration of NUMT-FP rates.

  • Open Access

    Population nuclear mitochondrial disease risk estimated from nuclear disease gene variants in a healthy older cohort

    by Eloise C Watson, Shyamsundar Ravishankar, Matthew Hobbs, Joseph Copty, Chenglong Yu, Sarah Kummerfeld, Christina Liang, Paul Lacaze, Ryan Davis, Carolyn M Sue

    Mitochondrial diseases (MDs) are genetically and phenotypically diverse and can be difficult to diagnose. Prevalence estimates derive largely from diagnosed cases and may underestimate population MD risk. Population-based studies are limited in scope and number but indicate MD variants are common. As genomic sequencing advances have made comprehensive population-based evaluation feasible, we sought to evaluate nuclear MD variation in a population cohort to understand variant prevalence and differences in MD risk estimates We identified disease-associated nuclear gene variants in 270 nuclear MD genes across 2,845 healthy older individuals in the Medical Genome Reference Bank. From Pathogenic or Likely Pathogenic Variants (PLPVs) we estimated autosomal recessive (AR) and autosomal dominant (AD) MD risk for individual genes and all nuclear variant-associated MDs. We identified 554 PLPV alleles representing 357 unique variants in 145 genes. Combined AR MD risk was estimated at 25.8 per 100,000 (95% CI 18.7 to 32.9), or 1 in 3,880 individuals. SPG7 (12.65 per 100,000; 95% CI 7.52-20.6) and POLG (4.23 per 100,000; 95% CI 2.10-8.01) contributed the greatest single gene AR MD risks and OPA1 variants posed the greatest AD MD risk. We observed a high rate of MD-associated nuclear gene variation in this healthy older cohort. The estimated lifetime AR MD risk was higher than commonly quoted prevalence estimates for all MDs, and the presence of common AD variants suggests variant penetrance may be lower than previously understood. These data help contextualise population MD risk and may inform clinical counselling and care.

  • Open Access

    Low disease risk and penetrance in Leber hereditary optic neuropathy

    by Eloise C. Watson, Ryan L. Davis, Shyamsundar Ravishankar, Joseph Copty, Sarah Kummerfeld, Carolyn M. Sue


  • Open Access

    Fundoscopy use in neurology departments and the utility of smartphone photography: a prospective prevalence and crossover diagnostic accuracy study amongst neurology inpatients

    by George He, Hamish P. Dunn, Kate E. Ahmad, Eloise Watson, Andrew Henderson, Dominique Tynan, John Leaney, Andrew J. White, Alex W. Hewitt, Clare L. Fraser

    Background and purpose: Although fundoscopy is a crucial part of the neurological examination, it is challenging, under‐utilized and unreliably performed. The aim was to determine the prevalence of fundus pathology amongst neurology inpatients and the diagnostic accuracy of current fundoscopy practice compared with systematic screening with smartphone fundoscopy (SF) and portable non‐mydriatic fundus photography (NMFP).Methods: This was a prospective cross‐sectional surveillance and diagnostic accuracy study on adult patients admitted under neurology in an Australian hospital. Inpatients were randomized to initial NMFP (RetinaVue 100, Welch Allyn) or SF (D‐EYE) followed by a crossover to the alternative modality. Images were graded by neurology doctors, using telemedicine consensus neuro‐ophthalmology NMFP grading as the reference standard. Feasibility parameters included ease, comfort and speed.Results: Of 79 enrolled patients, 14.1% had neurologically relevant pathology (seven, disc pallor; one, hypertensive retinopathy; three, disc swelling). The neurology team performed direct ophthalmoscopy in 6.6% of cases and missed all abnormalities. SF had a sensitivity of 30%–40% compared with NMFP (45.5%); however, it had a lower rate of screening failure (1% vs. 13%, p < 0.001), a shorter examination time (1.10 vs. 2.25 min, p < 0.001) and a slightly higher patient comfort rating (9.2 vs. 8/10, p < 0.001).Conclusion: Our study demonstrates a clinically significant prevalence of fundus pathology amongst neurology inpatients which was missed by current fundoscopy practices. Portable NMFP screening appears more accurate than SF, whilst both are diagnostically superior to routine fundoscopic practice, feasible and well tolerated by patients.


  • Gentamicin vestibulotoxicity is uncommon with modern dosing regimens: a prospective study using video head impulse testing (P6.043)

    by Duncan Smyth, Stuart Mossman, Mark Weatherall, Evan Jolliffe, Jennifer Taylor, Purwa Joshi, Katie Thorne, Eloise Watson, Ruth Leadbetter, Benjamin Mossman, et al.